Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression
Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression
复制标题
DOI：
10.1056/nejmoa2206443
复制
发表时间：
2022-11-03
影响因子：
158.5
通讯作者：
Malievskaia, Ekaterina
中科院分区：
文献类型：
--
作者：
Goodwin, Guy M.;Aaronson, Scott T.;Malievskaia, Ekaterina
方法在这个2期双盲试验中，我们随机分配患有难治性抑郁症的成年人接受单剂量的专利合成制剂裸盖菇素，剂量为25 mg，10 mg或1 mg（对照），沿着心理支持。主要终点是蒙哥马利-艾斯伯格抑郁评定量表（MADRS;范围，0 - 60，评分越高表明抑郁越严重）总评分从基线到第3周的变化。次要终点包括第3周的反应（MADRS总评分较基线降低>= 50%），第3周的缓解（MADRS总评分
BACKGROUNDPsilocybin is being studied for use in treatment-resistant depression.METHODSIn this phase 2 double-blind trial, we randomly assigned adults with treatmentresistant depression to receive a single dose of a proprietary, synthetic formulation of psilocybin at a dose of 25 mg, 10 mg, or 1 mg (control), along with psychological support. The primary end point was the change from baseline to week 3 in the total score on the Montgomery-Asberg Depression Rating Scale (MADRS; range, 0 to 60, with higher scores indicating more severe depression). Secondary end points included response at week 3 (>= 50% decrease from baseline in the MADRS total score), remission at week 3 (MADRS total score